Heterotrimeric G protein Gαs subunit attenuates PLEKHG2, a Rho family-specific guanine nucleotide exchange factor, by direct interaction.

Cell Signal

United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Yanagido1-1, Gifu 501-1193, Japan; Department of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University, Yanagido1-1, Gifu 501-1193, Japan. Electronic address:

Published: April 2017

PLEKHG2 is a Gβγ-dependent guanine nucleotide exchange factor (GEF) for the small GTPases Rac and Cdc42, and has been shown to mediate signalling pathways such as actin cytoskeleton reorganization and serum response element (SRE)-dependent gene transcription. Here we show that the constitutively active mutant of the Gαs subunit significantly attenuated PLEKHG2-induced SRE-mediated gene transcription. Strikingly, we observed that the constitutive activation of endogenous Gαs by treatment with CTx caused a similar inhibitory effect on PLEKHG2-induced activation of SRE. However, both the enforced expression of the catalytic subunit β of protein kinase A and the treatment with dibutyl-cyclic AMP failed to mimic the inhibitory effect of Gαs on PLEKHG2. Furthermore, the dominant negative mutant of protein kinase A had no effect on PLEKHG2-mediated SRE activation. Performing immunoprecipitation and an in vitro pulldown assay, we found that PLEKHG2 directly interacted with the active form of the Gαs subunit in cells. The interaction between PLEKHG2 and Gαs required the N-terminal region of PLEKHG2, which includes the DH domain, a functional domain of GEF, suggesting that Gαs directly masks the DH domain of PLEKHG2. In a previous study, we reported that Gβγ accelerates PLEKHG2-mediated SRE-dependent gene transcription. Interestingly, Gαs also inhibited the hyperactivation of SRE induced by the co-expression of Gβγ and PLEKHG2; however, Gαs and Gβγ bind to different regions of PLEKHG2. This is the first report to show that PLEKHG2 is a novel effector of Gαs, and is negatively regulated by the Gαs subunit through direct interaction.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2017.01.022DOI Listing

Publication Analysis

Top Keywords

gαs subunit
16
gene transcription
12
gαs
11
plekhg2
10
guanine nucleotide
8
nucleotide exchange
8
exchange factor
8
direct interaction
8
interaction plekhg2
8
sre-dependent gene
8

Similar Publications

Impaired angiogenesis is a significant factor contributing to delayed healing in diabetic foot ulcers (DFUs) due to inadequate oxygenation. This study aimed to investigate the impact of photobiomodulation (PBM) using a Ga-As laser on the release of serum hypoxia-inducible factor 1-α (HIF-1α), vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor-2, and nitric oxide (NO) in diabetic patients with DFUs. In this double-blind RCT, a total of 30 patients with grade II DFUs were enrolled.

View Article and Find Full Text PDF

GaAs laser therapy reestablishes the morphology of the NMJ and nAChRs after injury due to bupivacaine.

J Photochem Photobiol B

February 2017

Department of Anatomy, Institute of Biosciences, General Bases of Surgery, Botucatu Medical School, Brazil; UNESP, Botucatu, SP, Brazil. Electronic address:

Background: Local anesthetics are used to relieve pre- and postoperative pain, acting on both sodium channels and nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (NMJ). Bupivacaine acts as a non-competitive antagonist and has limitations, such as myotoxicity, neurotoxicity, and inflammation. Low-level laser therapy (LLLT) has anti-inflammatory, regenerative, and analgesic effects.

View Article and Find Full Text PDF

Recurrent high-grade gliomas (HGGs) of childhood have an exceedingly poor prognosis with current therapies. Accordingly, new treatment approaches are needed. We initiated a pilot trial of vaccinations with peptide epitopes derived from glioma-associated antigens (GAAs) overexpressed in these tumors in HLA-A2+ children with recurrent HGG that had progressed after prior treatments.

View Article and Find Full Text PDF

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.

Neuro Oncol

August 2016

Department of Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania (I.F.P., H.O.); Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania (R.I.J., A.K.C., S.D., G.M.); Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (R.L.H., T.L.W.); Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania (L.H.B.), Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania (L.H.B., H.O.), Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania (A.P.), Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania (L.H.B., T.L.W.), University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania (I.F.P., R.I.J., A.P., A.K.C., S.D., G.M.); University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania (I.F.P., R.I.J., L.H.B., R.L.H., D.P.N., G.M., T.L.W., H.O.); Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania (D.P.N.); Department of Neurosurgery, University of CaliforniaSan Francisco, San Francisco, California (H.O.).

Background: Low-grade gliomas (LGGs) are the most common brain tumors of childhood. Although surgical resection is curative for well-circumscribed superficial lesions, tumors that are infiltrative or arise from deep structures are therapeutically challenging, and new treatment approaches are needed. Having identified a panel of glioma-associated antigens (GAAs) overexpressed in these tumors, we initiated a pilot trial of vaccinations with peptides for GAA epitopes in human leukocyte antigen-A2+ children with recurrent LGG that had progressed after at least 2 prior regimens.

View Article and Find Full Text PDF

Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

Clin Cancer Res

January 2015

Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Purpose: WHO grade 2 low-grade gliomas (LGG) with high risk factors for recurrence are mostly lethal despite current treatments. We conducted a phase I study to evaluate the safety and immunogenicity of subcutaneous vaccinations with synthetic peptides for glioma-associated antigen (GAA) epitopes in HLA-A2(+) adults with high-risk LGGs in the following three cohorts: (i) patients without prior progression, chemotherapy, or radiotherapy (RT); (ii) patients without prior progression or chemotherapy but with prior RT; and (iii) recurrent patients.

Experimental Design: GAAs were IL13Rα2, EphA2, WT1, and Survivin.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!